Sangamo Therapeutics (SGMO) added ~9% in the premarket on Friday after the gene therapy developer said that the U.S. FDA ...

Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort.

Targeted cancer therapies like CDK4/6, EGFR, VEGFR, and BRAF inhibitors may increase long-term kidney dysfunction risk. Learn ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.

Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...

Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline ...

Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...

Expert discusses how the prevalence of chronic kidney disease (CKD), as reflected by decreased estimated glomerular ...

Joanne Cure, 78, survived stage 4 lung cancer after being given two years to live, crediting her faith, determination, and ...

H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $26 from $24 and keeps a Buy rating on the shares Cullinan and ...

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...